AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17708607
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) therapy for 3 weeks
Trial: 15087291
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g intravenous ascorbic acid (AA)
Trial: 8048508
Drug: Chloroquine 250
RxNorm normalized name: chloroquine 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 250 mg
Trial: 8048508
Drug: Chloroquine 500
RxNorm normalized name: chloroquine 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 500 mg
Trial: 182105
Drug: Thyrotropin-releasing factor
RxNorm normalized name: Thyrotropin-releasing factor
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thyrotropin-releasing factor (TRF) 43 mg daily for 4 weeks
Trial: 24283084
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of spinal plain bupivacaine only (Group B)
Trial: 24283084
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg plain bupivacaine with 25 mcg of fentanyl (Group BF)
Trial: 21904105
Drug: roxithromycin 300
RxNorm normalized name: roxithromycin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 300 mg
Trial: 18798807
Drug: Time taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time taken to return to normal activities after treatment
Trial: 16421404
Drug: SonoVue (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SonoVue (various doses: 0.3 ml, 0.6 ml, 1.2 ml, 2.4 ml)
Trial: 8343473
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C 0.4 mg/ml (0.04%) eye drops, four times a day for 2 weeks post-surgery
Trial: 30167757
Drug: Voriconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (400 mg twice on day 1 and 200 mg twice on days 2-5)
Trial: 26104432
Drug: Step-down treatment
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down treatment program (short-term day-hospital treatment followed by outpatient combined group and individual psychotherapy)
Trial: 22836071
Drug: Pitavastatin 2-4
RxNorm normalized name: pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2-4 mg/day (PITA, n = 97)
Trial: 22836071
Drug: Atorvastatin 10-20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10-20 mg/day (ATOR, n = 92)
Trial: 22836071
Drug: Atorvastatin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (n = 67)
Trial: 22836071
Drug: Atorvastatin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (n = 20)
Trial: 18778758
Drug: Benserazide (inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benserazide (inhibitor of extracerebral dopa decarboxylase)
Trial: 18778758
Drug: Carbidopa (inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa (inhibitor of extracerebral dopa decarboxylase)
Trial: 16154437
Drug: Hydroxocobalamin (HC)
RxNorm normalized name: Hydroxocobalamin
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxocobalamin (HC) 1 mg intravenous weekly for 8 weeks
Trial: 16154437
Drug: Cyanocobalamin (CC)
RxNorm normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyanocobalamin (CC) for 8 weeks
Trial: 16154437
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to alternate form (HC or CC)
Trial: 10765065
Drug: Finasteride (5α-reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5α-reductase inhibitor)
Trial: 10765065
Drug: GI198745 (dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GI198745 (dual 5α-reductase inhibitor)
Trial: 2049752
Drug: POG protocol
RxNorm normalized name: Pogostemon cablin top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POG protocol 8303 (four-drug systemic reinduction: prednisone, vincristine, daunorubicin, and asparaginase; brief intensive consolidation with teniposide and cytarabine; continuation chemotherapy with weekly rotating drug pairs; bilateral testicular radiation (2600 cGy); intrathecal chemoprophylaxis every 4 to 6 weeks)
Trial: 6589968
Drug: Cranial radiation
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial radiation and chemotherapy
Trial: 6589968
Drug: Longer duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer duration of chemotherapy
Trial: 6589968
Drug: Dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose of cranial radiation, concomitant intrathecal methotrexate therapy, and duration of therapy
Trial: 27621597
Drug: AZD1981 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1981 1,000 mg bid
Trial: 27621597
Drug: AZD1981 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1981 50 mg bid
Trial: 27621597
Drug: AZD1981 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1981 400 mg bid
Trial: 21051656
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg lasofoxifene
Trial: 18052570
Drug: Risperidone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2 to 4 mg/day for 1 year)
Trial: 18052570
Drug: Haloperidol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2 to 4 mg/day for 1 year)
Trial: 16047123
Drug: Atropine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.01 mg/kg) administered intravenously 3 min prior to treadmill stress
Trial: 16047123
Drug: No atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No atropine administered (Control)
Trial: 7625665
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliovirus vaccine (OPV)
Trial: 7625665
Drug: Combined diphtheria
RxNorm normalized name: tetanus toxoid, combinations with diphtheria toxoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined diphtheria and tetanus toxoids and pertussis vaccine with IPV
Trial: 2515822
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (acylated streptokinase, intravenous bolus of 30 units in 4 minutes)
Trial: 28295445
Drug: ω‐3 EFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 EFA supplements (1000 mg/day eicosapentaenoic acid + 500 mg/day docosahexaenoic acid)
Trial: 25271015
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters (4 g) in a high-fat shake
Trial: 25271015
Drug: Plant stanol-enriched
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol-enriched margarine (3 g/day)
Trial: 18337741
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity administered by the infant's mother (MOM)
Trial: 18337741
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity administered by a trained therapist (OT)
Trial: 17065618
Drug: Daptomycin 6
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 6 mg/kg once daily
Trial: 17065618
Drug: Daptomycin 6
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 6 mg/kg once daily plus Gentamicin 1 mg/kg every 8 h
Trial: 14998110
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and behavioral treatment (Comb)
Trial: 11335792
Drug: CsA 10
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA 10 mg/kg
Trial: 11335792
Drug: CsA 5
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA 5 mg/kg
Trial: 9330586
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (15 mg/kg body weight/day)
Trial: 9330586
Drug: Nicotinamide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (25 mg/kg body weight/day)
Trial: 7883133
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy (SK or rtPA)
Trial: 18307280
Drug: NSAID treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID treatment (indomethacin or celebrex) for three days preoperatively
Trial: 10716466
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (NA) (mean dose 2,250 mg/day)
Trial: 10716466
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of gemfibrozil plus NA
Trial: 10716466
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy vs. gemfibrozil alone
Trial: 10716466
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy vs. NA alone
Trial: 9184390
Drug: Fixed minidose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed minidose warfarin 1.25 mg/day
Trial: 9184390
Drug: Combined minidose
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined minidose warfarin (1.25 mg/day) and aspirin (300 mg/day)
Trial: 9184390
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose adjusted warfarin (INR 2.0-3.0)
Trial: 3816922
Drug: Alinidine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alinidine 40 mg p.o.
Trial: 25639140
Drug: Animal-source food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-source food supplement 5 days per week from marriage to term (approximately 13 months)
Trial: 25639140
Drug: Animal-source food
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal-source food supplement 5 days per week from 16 weeks of gestation to term (approximately 5 months)
Trial: 18160963
Drug: Standard hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hepatitis B vaccine (double doses)
Trial: 18160963
Drug: Booster doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster doses of HBV‐AS04
Trial: 7723156
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention to promote adherence to a diet providing 28% of energy from total fat, less than 8% from saturated fat, up to 9% from polyunsaturated fat, and less than 75 mg/4200 kJ (1000 kcal) per day of cholesterol (not to exceed 150 mg/d)
Trial: 31342138
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1.2 g/d of elemental calcium in the form of calcium carbonate)
Trial: 28779963
Drug: 36 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group)
Trial: 28779963
Drug: Reduced-dose and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose and partial-breast radiotherapy
Trial: 23033005
Drug: Capecitabine (cape)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (cape) treatment with HFSR
Trial: 23033005
Drug: Capecitabine (cape)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (cape) treatment without HFSR
Trial: 19796562
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E gel (D-alpha-tocopheryl acetate) applied twice a week
Trial: 18079221
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg/d for 4 weeks)
Trial: 10745058
Drug: Testosterone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (250 mg testosterone enanthate)
Trial: 8942440
Drug: Early versus
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early versus deferred antiretroviral treatment
Trial: 1561479
Drug: 200 UI/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 UI/day of salmon calcitonin (CT) by nasal spray
Trial: 1561479
Drug: Placebo by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by nasal spray
Trial: 27364372
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) group: initial arthrocentesis plus PRP injection and then four consecutive PRP injections.
Trial: 27364372
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) group: one session of arthrocentesis plus HA injection.
Trial: 20650471
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline 2.5 mg
Trial: 20650471
Drug: 20% basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% basal rate insulin reduction for 6 hours
Trial: 18757014
Drug: Drained serums
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drained serums prepared by an infusion system and a three-way valve
Trial: 15914526
Drug: rhGH (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (6 mg SC daily)
Trial: 12769161
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors and low-dose diuretics
Trial: 11379860
Drug: 1.1% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% amino acid dialysis solution (AADS)
Trial: 11379860
Drug: Standard dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysis solutions (control)
Trial: 15321377
Drug: SM: 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM: 0.1 mg
Trial: 15321377
Drug: SM: 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM: 0.2 mg
Trial: 15321377
Drug: SM: 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM: 0.1 mg plus K 60 mg i.v. one hour after spinal injection, and 30 mg i.v. every 6 h for three doses
Trial: 26988231
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature stable carbetocin (100 μg intramuscular)
Trial: 26988231
Drug: Oxytocin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (10 IU intramuscular)
Trial: 24359507
Drug: Escitalopram 10
RxNorm normalized name: escitalopram 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 10 mg/day with cognitive-behavior and motivation-enhancement therapy
Trial: 24359507
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with cognitive-behavior and motivation-enhancement therapy
Trial: 22480131
Drug: Fentanyl sublingual
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl sublingual spray (100-1600 mcg)
Trial: 20574411
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal gel (0.05%)
Trial: 20574411
Drug: Gel 4789
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel 4789 (Dapivirine vaginal gel)
Trial: 20574411
Drug: Hydroxyethyl cellulose-based
RxNorm normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl cellulose-based universal placebo gel
Trial: 15868442
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment in patients with moderate cyclin D1 expression
Trial: 8689817
Drug: R(+)‐terodiline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R(+)‐terodiline hydrochloride (100 mg)
Trial: 8689817
Drug: Racemic terodiline
RxNorm normalized name: terodiline
DrugBank: Terodiline (DB13725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic terodiline hydrochloride (200 mg)
Trial: 8689817
Drug: S(‐)‐terodiline tartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(‐)‐terodiline tartrate (100 mg)
Trial: 27910185
Drug: Paclitaxel drug-eluting
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel drug-eluting balloon (DEB) angioplasty
Trial: 24402636
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (30 mg/day of zinc gluconate for 8 weeks)
Trial: 11923554
Drug: Intrapleural urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural urokinase 40,000 units in 40 ml, administered 12 hourly for 3 days
Trial: 11923554
Drug: Saline (placebo),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (placebo), administered 12 hourly for 3 days
Trial: 11923554
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of urokinase and small percutaneous drain
Trial: 7658954
Drug: Progressive Resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive Resistance Training (PRT) at 80% or more of 1RM, training twice weekly for 12 months.
Trial: 1106447
Drug: oxazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxazepam (30 mg) and alcohol (0.75 g/kg) combined
Trial: 1106447
Drug: alcohol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alcohol (0.75 g/kg)
Trial: 26036329
Drug: Topical 30%
RxNorm normalized name: urea topical 30% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 30% resin lacquer once daily for 9 months
Trial: 26036329
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% amorolfine lacquer once weekly for 9 months
Trial: 26036329
Drug: Oral terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbinafine 250 mg once daily for 3 months
Trial: 26036329
Drug: Topical 30%
RxNorm normalized name: urea topical 30% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 30% resin lacquer
Trial: 26036329
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% amorolfine lacquer
Trial: 20084896
Drug: rBS/WC oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBS/WC oral cholera vaccine
Trial: 16680923
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate DPI, 200 microg, once daily in the evening
Trial: 15166553
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propofol and remifentanil
Trial: 2663386
Drug: External shock-wave
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External shock-wave lithotripsy (ESL) and adjuvant ursodiol therapy
Trial: 2663386
Drug: Ursodiol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodiol therapy alone
Trial: 4574639
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks cyclophosphamide therapy
Trial: 4574639
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks cyclophosphamide therapy
Trial: 4574639
Drug: steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid treatment alone
Trial: 25370206
Drug: 100-mg sildenafil
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg sildenafil
Trial: 2249406
Drug: 1 mgF-
RxNorm normalized name: ALLANTOIN 0.5 in 25 g TOPICAL PATCH [Cellapy MGF Hydro Gel Intense Mask]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mgF- tablets plus fortnightly rinsing at school with 1000 ppmF-
Trial: 2249406
Drug: 1 mgF-
RxNorm normalized name: ALLANTOIN 0.5 in 25 g TOPICAL PATCH [Cellapy MGF Hydro Gel Intense Mask]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mgF- tablets plus placebo rinsing